SCHEMBL23930577

SCHEMBL23930577

COC(=O)c1cc(OC(F)F)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 2/20 0.38
SMPD1 P17405 1/20 0.37
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
GPR65 Q8IYL9 1/20 0.34
TP53 P04637 1/20 0.34
P2RX3 P56373 1/20 0.34
HTT P42858 2/20 0.33
MME P08473 1/20 0.33
NR1I2 O75469 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963198 0.85 CHRNA4 (0.39) CHRNA4SMPD1NR1H2NR1H3MAPT
SCHEMBL23930562 0.83 SMPD1 (0.35) CHRNA4SMPD1ALDH1A1KDM4EKMT2A
SCHEMBL23930613 0.81 HCAR2 (0.47) CHRNA4SMPD1MME
SCHEMBL5752843 0.81 NR1H2 (0.39) CHRNA4SMPD1NR1H2NR1H3MAPT
SCHEMBL1536321 0.81 CHRNA4 (0.52) CHRNA4SMPD1MAPTALDH1A1KDM4E
SCHEMBL23930612 0.79 RAB9A (0.35) CHRNA4SMPD1ALDH1A1KDM4EHTT
SCHEMBL6966899 0.78 KDM4E (0.42) CHRNA4SMPD1MAPTALDH1A1KDM4E
SCHEMBL19556161 0.78 HTT (0.40) MAPTALDH1A1KDM4ECYP1A2CYP2C19
SCHEMBL9111559 0.77 SMPD1 (0.40) CHRNA4SMPD1NR1H2NR1H3MAPT
SCHEMBL23930602 0.76 SMPD1 (0.33) SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697979-B Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2025-06-24 CN disclosed
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG CHRNA4 3677/4885SMPD1 510/4885NR1H2 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.